Q4

Emcure Pharmaceuticals Ltd

EMCUREFY2605 May 2026

Revenue+4.5%

Net Profit+5.3%

OPM19.83%

P&L

Quarterly Consolidated

Revenue

+4.5%2.5K

Expenditure

+6.4%2.1K

Net Profit

+5.3%243.74

NPM 9.85%+0.7%EPS ₹12.84+5.6%

vs Q3 FY26

Informational and educational content only. Not investment advice.